Natalizumab antibody clinical trial

Natalizumab has been shown to slow the progression of MS in people with the disease and reduce the rate of relapses in people with relapsing-remitting MS. In a randomized, placebo-controlled study, 77% of patients were relapse-free after 1 year. The 2-year recurrence-free rate in the natalizumab group was 67%. When comparing MRI images of participants who received natalizumab and placebo, the results showed that patients who received natalizumab had an 83% reduction in the number of lesions detected on T2-weighted MRI and an 83% reduction in lesions on gadolinium-enhanced MRI images compared to patients who received placebo.